Group 1: Industry Overview - The overall revenue growth rate for the pharmaceutical and biotechnology sector in Q1 2025 was -4.8%, with a net profit growth rate of -12.2%[3] - The raw material drug sector showed resilience with a revenue growth rate of -3.6% and a net profit growth rate of 10.5% in Q1 2025, benefiting from demand recovery and price stabilization[3] Group 2: Profitability and Financial Performance - In 2024, major raw material drug companies saw an increase in gross margin and net margin by 0.78 percentage points and 0.39 percentage points respectively, while Q1 2025 saw a decline in average gross margin and net margin by 0.64 percentage points and 1.87 percentage points respectively[5] - The average operating cash flow for major raw material drug companies reached 10.04 billion yuan in 2024, a 14.65% increase from 2023, indicating a positive trend[31] Group 3: Capital Expenditure Trends - Capital expenditure for major raw material drug companies in 2024 totaled 7.242 billion yuan, reflecting a year-over-year decrease of 4.12%[36] - The capital expenditure to depreciation ratio for the raw material drug sector decreased from 1.79 in 2023 to 1.27 in 2024, indicating ongoing capacity reduction and structural adjustments[36] Group 4: Investment Strategy - Investment recommendations focus on selecting raw material drug companies with strong growth attributes and stable competitive landscapes, particularly in bulk and specialty raw materials[44] - Companies like Guobang Pharmaceutical and Tianyu Co., Ltd. are highlighted for their favorable supply dynamics and demand recovery[44] Group 5: Risk Factors - Risks include intensified competition leading to suboptimal recovery in product prices and volumes, production safety incidents, and exchange rate fluctuations impacting profitability[47]

Investment Rating - The investment rating for the company is "Add" [1] Core Views - The company is raising 500 million RMB through a directed issuance, fully subscribed by the actual controller, indicating strong confidence in the company's future [7] - The clinical pipeline is progressing smoothly with multiple catalysts on the horizon, including the initiation of Phase II clinical trials for BGM0504, which shows promising weight loss results compared to competitors [7] - The company maintains its profit forecast, expecting net profits of 262 million RMB in 2025 and 303 million RMB in 2026, with a new forecast of 433 million RMB for 2027 [7] Financial Summary - Total revenue is projected to grow from 1,283 million RMB in 2024 to 1,762 million RMB in 2027, with a compound annual growth rate (CAGR) of 15.11% from 2026 to 2027 [8] - The net profit attributable to the parent company is expected to increase from 189 million RMB in 2024 to 433 million RMB in 2027, reflecting a significant growth trajectory [8] - The earnings per share (EPS) is forecasted to rise from 0.45 RMB in 2024 to 1.03 RMB in 2027, indicating improved profitability [8]

Core Viewpoint - The company is preparing for its 2024 Annual General Meeting (AGM) and is seeking shareholder approval for extending the authorization for the board to issue A-shares to specific targets, while also reporting on its operational performance and strategic initiatives for the year [1][6][19]. Group 1: Meeting Procedures and Regulations - The AGM will ensure the orderly conduct of the meeting, allowing only authorized participants to enter [1][2]. - Shareholders must register 30 minutes before the meeting and present identification to participate in voting [2][4]. - The meeting will follow a structured agenda, including the presentation of proposals, shareholder questions, and voting procedures [5][6]. Group 2: Financial Performance - The company's net profit for the year is reported at 189.17 million yuan, a decrease of 6.57% year-on-year [7][30]. - The net profit attributable to shareholders after excluding non-recurring gains and losses is 180.51 million yuan, reflecting a 3.12% decline compared to the previous year [7][30]. Group 3: Research and Development Initiatives - The company has increased its R&D investment, with a total of 62.78% of R&D spending directed towards innovative drugs and inhalation formulations, marking a 77.37% increase year-on-year [8][9]. - The company is focusing on developing innovative drugs in the metabolic disease sector, particularly the BGM0504 injection, which has received ethical approval for phase III clinical trials in China [9][10]. Group 4: Strategic Development and Market Expansion - The company aims to enhance its global competitiveness by developing high-end generic drugs and original new drugs, with a focus on unmet clinical needs [21][22]. - The company is actively pursuing international collaborations and investments to expand its market presence, including establishing a joint venture in Indonesia [17][23]. Group 5: Corporate Governance and Compliance - The company emphasizes compliance with legal regulations and internal controls to protect shareholder interests and ensure effective governance [28][29]. - The supervisory board has conducted regular reviews of financial practices and internal controls, confirming the integrity of financial reporting [28][29].

博瑞生物医药（苏州）股份有限公司 2024 年年度股东大会会议资料 博瑞生物医药（苏州）股份有限公司 2024 年年度股东大会会议资料 二〇二五年五月 | | | | | | 第 1页/共 51页 六、 股东要求在股东大会现场会议上发言，应提前到发言登记处进行登记 （发言登记处设于大会签到处）。大会主持人根据发言登记处提供的名单和顺序 第 4页/共 51页 博瑞生物医药（苏州）股份有限公司 2024 年年度股东大会会议资料 博瑞生物医药（苏州）股份有限公司 2024 年年度股东大会会议资料 2024 年年度股东大会会议须知 为维护全体股东的合法权益，确保股东大会会议秩序和议事效率，保证股东 大会的顺利召开，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东大会规 则》以及《博瑞生物医药（苏州）股份有限公司章程》（以下简称"《公司章程》"） 和博瑞生物医药（苏州）股份有限公司（以下简称"公司"、"上市公司"或"博 瑞医药"）《股东大会议事规则》等有关规定，特制定 2024 年年度股东大会会 议须知： 一、 为保证本次大会的严肃性和正常秩序，切 ...

Group 1 - Yitong Century won a bid for a communication engineering construction service project from China Mobile, with a total bid amount of 228 million yuan (including tax) [1] - Zhiyuan New Energy plans to repurchase shares worth between 33 million and 66 million yuan, with a maximum repurchase price of 22.00 yuan per share [1] - GAC Group reported April automobile sales of 116,400 units, a year-on-year decrease of 12.66% [2] - JAC Motors reported April automobile sales of 30,764 units, a year-on-year decrease of 3.55% [3] Group 2 - Fosun Pharma's subsidiary received FDA approval for a clinical trial of a live biotherapeutic product aimed at treating androgenetic alopecia [4] - Liangxin Co. obtained multiple patent certificates, including 2 invention patents and 32 utility model patents [5] - Sainuo Medical's two products received medical device registration certificates in Mexico and Ecuador [5] - Huayu Pharmaceutical's two products received marketing approvals in France and Spain [6] Group 3 - Shengnong Development reported April sales revenue of 1.533 billion yuan, a year-on-year increase of 0.68% [6] - Hasi Lian's potassium chloride and sodium chloride injection passed the consistency evaluation [7] - Shapuaisi received approval for a supplemental application for levofloxacin eye drops [9] - Tianyu Biological reported April sales revenue of 59.32 million yuan from pig sales [10] Group 4 - *ST Weihai was pre-awarded a project worth 108 million yuan [12] - Luoniushan reported April sales revenue of 125 million yuan from pig sales, a year-on-year increase of 12.72% [13] - Minhe Co. reported April sales revenue of 68.30 million yuan from chick sales, a year-on-year increase of 0.51% [14] Group 5 - Double Ring Technology's application for a specific stock issuance was approved by the Shenzhen Stock Exchange [15] - Hualu Hengsheng plans to repurchase shares worth between 200 million and 300 million yuan [16] - Baolong Technology plans to repurchase shares worth between 100 million and 200 million yuan [17] Group 6 - Huasheng Technology's subsidiary plans to sell shares of a company for 200 million yuan [24] - *ST Gengxing's controlling shareholder plans to increase holdings worth between 30 million and 60 million yuan [25] - Ruihuatai's shareholder plans to reduce holdings by up to 1% of the company's shares [26] Group 7 - Foton Motor reported April commercial vehicle sales of 54,816 units, a year-on-year increase of 21.63% [20] - China Merchants Bank plans to invest 15 billion yuan to establish a financial asset investment company [22] - Jinchengxin plans to invest approximately 231 million USD in the Alacran copper-gold-silver mine project [23] Group 8 - Zhongji United's controlling shareholder plans to reduce holdings by up to 2% of the company's shares [30] - Ningbo Huaxiang signed a strategic cooperation agreement to strengthen collaboration in various areas [31] - SMIC reported a net profit of 1.356 billion yuan for Q1 2025, a year-on-year increase of 166.5% [32] Group 9 - FAW Fuwi received a project notification to develop seat products for a luxury brand, with a total sales amount expected to be 1.39 billion yuan [33] - Huakang Clean won a bid for a purification project worth 64.425 million yuan [34] - Lihua Co. reported April sales revenue of 1.125 billion yuan from chicken sales [35]

Investment Rating - The investment rating for the company is "Add" [1] Core Views - The company is raising 500 million RMB through a directed issuance, fully subscribed by the actual controller, indicating strong confidence in the company's future [7] - The clinical pipeline is progressing smoothly with multiple catalysts on the horizon, particularly the BGM0504 and BGM1812 projects [7] - The company is expected to maintain its profit forecasts, with projected net profits of 2.6 billion RMB in 2025 and 3.0 billion RMB in 2026, and a new forecast of 4.3 billion RMB for 2027 [7] Financial Projections - Total revenue is projected to reach 1,283 million RMB in 2024, with a growth rate of 8.74% [8] - The net profit attributable to the parent company is expected to be 189 million RMB in 2024, with a year-on-year decrease of 6.57% [8] - The earnings per share (EPS) is forecasted to be 0.45 RMB in 2024, increasing to 1.03 RMB by 2027 [8] Market Data - The closing price of the stock is 51.35 RMB, with a market capitalization of approximately 21,693.81 million RMB [5] - The price-to-earnings (P/E) ratio is projected to be 114.68 for 2024, decreasing to 50.06 by 2027 [8] Pipeline Developments - The company has initiated a Phase II clinical trial for BGM0504, which shows promising weight loss results compared to the competitor drug, Tirzepatide [7] - BGM1812, a long-acting amylin analog, is expected to enter clinical stages soon, highlighting the potential for significant market opportunities [7]

证券代码：688166 证券简称：博瑞医药 公告编号：2025-025 博瑞生物医药（苏州）股份有限公司 关于申请注册发行中期票据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 注册发行总金额：拟注册发行中期票据不超过人民币 3 亿元（含 3 亿元） 发行期限：不超过 5 年（含 5 年） 已履行的审议程序：本事项已经第四届董事会第六次会议审议通过，尚 需提交公司股东大会审议 为拓宽公司融资渠道，降低融资成本，根据《中华人民共和国公司法》《银 行间债券市场非金融企业债务融资工具管理办法》等相关规定，结合业务发展需 要，博瑞生物医药（苏州）股份有限公司（以下简称"公司"）拟向中国银行间 市场交易商协会申请注册发行不超过 3 亿元（含 3 亿元）的中期票据，并在中期 票据注册额度有效期内，根据市场情况以及公司自身资金需求状况在中国境内一 次或分期发行。详情如下： 一、发行方案 （一）注册发行规模：拟注册发行中期票据的规模为不超过人民币 3 亿元（含 3 亿元），具体发行规模将以公司在中国银行间市场交易商 ...

博瑞生物医药（苏州）股份有限公司 关于 2024 年度向特定对象发行 A 股股票预案（修订稿） 披露的提示性公告 证券代码：688166 证券简称：博瑞医药 公告编号：2025-019 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）于 2025 年 5 月 8 日召开第四届董事会第六次会议、第四届监事会第六次会议，会议审议通过了关 于公司 2024 年度向特定对象发行 A 股股票预案（修订稿）的议案等相关议案。 《博瑞生物医药（苏州）股份有限公司 2024 年度向特定对象发行 A 股股票 预案（修订稿）》《博瑞生物医药（苏州）股份有限公司 2024 年度向特定对象发 行 A 股股票方案的论证分析报告（修订稿）》等相关文件于同日在上海证券交易 所网站（www.sse.com.cn）披露，敬请广大投资者注意查阅。 本次公司 2024 年度向特定对象发行 A 股股票预案的披露事项不代表审核、 注册部门对于本次发行相关事项的实质性判断、确认或批准，向特定对象发行股 票预案所述本次发行相关事项的生效和完成尚待上海证券交易所审核并经中国 证券监督管理委员会注册。敬请广大投资者注意投资风险。 特此公告。 博瑞生物医药 ...

证券简称：博瑞医药 证券代码：688166 博瑞生物医药（苏州）股份有限公司 BrightGene Bio-Medical Technology Co., Ltd. （苏州工业园区星湖街 218 号纳米科技园 C25 栋） 2024 年度向特定对象发行 A 股股票预案 （修订稿） 二〇二五年五月 1 公司声明 1、公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不存 在虚假记载、误导性陈述或重大遗漏。 2、本预案按照《上市公司证券发行注册管理办法》等法规及规范性文件的 要求编制。 3、本次向特定对象发行股票完成后，公司经营与收益的变化由公司自行负 责；因本次向特定对象发行股票引致的投资风险，由投资者自行负责。 4、本预案是公司董事会对本次向特定对象发行股票的说明，任何与之相反 的声明均属不实陈述。 5、投资者如有任何疑问，应咨询自己的股票经纪人、律师、专业会计师或 其他专业顾问。 6、本预案所述事项并不代表审批机关对于本次向特定对象发行股票相关事 项的实质性判断、确认、批准或核准，本预案所述本次向特定对象发行股票相关 事项的生效和完成尚待公司股东大会审议通过、上海证券交易所审核通过并经中 国证监会作 ...

证券简称：博瑞医药 证券代码：688166 博瑞生物医药（苏州）股份有限公司 BrightGene Bio-Medical Technology Co., Ltd. （苏州工业园区星湖街 218 号纳米科技园 C25 栋） 2024 年度向特定对象发行 A 股股票 方案的论证分析报告（修订稿） $$\Xi{\cal O}\,{\underline{{{-\,}}}}\,{\mit\Pi}\,{\not\Xi}\,{\mit\Pi}\,{\not\Xi}$$ 1 博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"或"公司"） 是上海证券交易所科创板上市的公司。为了进一步提升公司创新能力，满足业务 发展需求和实现发展战略，同时优化公司资本结构，增强抗风险能力和盈利能力， 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国 证券法》（以下简称"《证券法》"）和《上市公司证券发行注册管理办法》（以 下简称"《注册管理办法》"）等有关法律、行政法规、部门规章或规范性文件 和《公司章程》的规定，公司编制了 2024 年度向特定对象发行 A 股股票方案的 论证分析报告（以下简称"本论证分析报告"）。 ...